Restructure Information
On September 15, 2019, Purdue announced a preliminary agreement for settling the massive opioid litigation facing the Company.
To implement this settlement and secure a final resolution of all pending litigation, Purdue and its subsidiaries have voluntarily filed petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code.
Adlon Therapeutics L.P. is a biopharmaceutical company dedicated to developing and providing treatment options for ADHD and related disorders. Our initial focus is on adults and adolescents who suffer from symptoms of Attention Deficit/Hyperactivity Disorder (ADHD). Adlon is a subsidiary of Purdue Pharma L.P.
Adhansia XR™
(Methylphenidate Hydrochloride) Extended-Release Capsules CII
Warning: Abuse and Dependence
CNS stimulants, including Adhansia XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.
